A new study reports no statistically significant increase in the risk of bladder cancer among patients treated with the diabetes drug pioglitazone (Actos), despite previous studies suggesting an association.
However, the authors, led by Assiamira Ferrara, MD, PhD, of Kaiser Permanente Northern California, Oakland, did find a possible link between pioglitazone and prostate and pancreatic cancer. They reported their findings in JAMA (2015; 314:265-77).
Related - Best of AUA 2015: Bladder Cancer
To explore the relationship between pioglitazone and bladder cancer, the investigators performed a cohort analysis of 193,099 diabetic patients and a nested case-control analysis of 464 bladder cancer patients and 464 matched controls. The patients, who were all 40 years of age or older in 1997 through 2002 and from Kaiser Permanente Northern California, were followed until December 2012.
A second cohort analysis of 236,507 patients, also from Kaiser Permanente and 40 years of age or older in 1997 through 2005, considered pioglitazone in relation to 10 additional cancers (prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectum, and melanoma). It followed the patients until June 2012.
Want more Urology Times?